Head to Head Comparison: Sunshine Biopharma (SBFM) and The Competition

Posted by Defense World Staff on Apr 12th, 2023

Sunshine Biopharma (NASDAQ:SBFM – Get Rating) is one of 992 public companies in the “Pharmaceutical preparations” industry, but how does it contrast to its competitors? We will compare Sunshine Biopharma to similar companies based on the strength of its institutional ownership, profitability, risk, valuation, dividends, earnings and analyst recommendations.

Profitability

This table compares Sunshine Biopharma and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sunshine Biopharma	-615.37%	-91.27%	-85.23%
Sunshine Biopharma Competitors	-3,398.06%	-233.86%	-35.55%

Risk and Volatility

Sunshine Biopharma has a beta of 2.15, meaning that its stock price is 115% more volatile than the S&P 500. Comparatively, Sunshine Biopharma’s competitors have a beta of 0.91, meaning that their average stock price is 9% less volatile than the S&P 500.

Insider & Institutional Ownership

18.3% of Sunshine Biopharma shares are held by institutional investors. Comparatively, 40.5% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 5.0% of Sunshine Biopharma shares are held by insiders. Comparatively, 15.6% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Sunshine Biopharma and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Sunshine Biopharma	$4.35 million	-$26.74 million	-0.35
Sunshine Biopharma Competitors	$1.82 billion	$241.41 million	-3.67

Sunshine Biopharma’s competitors have higher revenue and earnings than Sunshine Biopharma. Sunshine Biopharma is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a breakdown of current ratings for Sunshine Biopharma and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sunshine Biopharma	0	0	0	0	N/A
Sunshine Biopharma Competitors	4207	15079	41555	713	2.63

As a group, “Pharmaceutical preparations” companies have a potential upside of 116.41%. Given Sunshine Biopharma’s competitors higher possible upside, analysts plainly believe Sunshine Biopharma has less favorable growth aspects than its competitors.

Summary

Sunshine Biopharma competitors beat Sunshine Biopharma on 6 of the 10 factors compared.

About Sunshine Biopharma

(Get Rating)

Sunshine Biopharma, Inc. engages in the research, development, and commercialization of oncology and antiviral drugs. It is also involved in the development and commercialization of science-based nutritional supplements. Its products include treatment for Coronavirus infections and anticancer drugs. The company was founded on August 31, 2006 and is headquartered in Pointe-Claire, Canada.

Receive News & Ratings for Sunshine Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.